Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree - 2Grasping the Course of Evacuation and Extradition in U.S. Migration
- 3Holiday destinations for Creature Sweethearts
- 4Hundreds of Intact Dinosaur Eggs Emerge From 72-Million-Year Time Capsule
- 5Visual communication Programming for Fledglings
- 5 Language Learning Applications
- Hilary Duff releases 'Mature,' her 1st song in 10 years
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- Japan deploys the military to counter a surge in bear attacks
- Colorado residents face earliest water restrictions ever — a harbinger of worse to come
- Instructions to Floss Appropriately and Forestall Gum Sickness
- Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa
- Exploring School Life: Self-awareness and Illustrations
- ICAS calls for clearer safeguards in FRC’s TCA policy
